Search clinical trials for: Fondaparinux sodium

Total 10440 results

Lehigh Valley Hospital
GlaxoSmithKline

Terminated

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients (BRiEF)

Venous Thrombosis

United States
NYU Langone Health
GlaxoSmithKline

Withdrawn

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

Ovarian Carcinoma

United States
GlaxoSmithKline

Completed

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)

Cardiovascular Disease
University of Pittsburgh
GlaxoSmithKline

Completed

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

Venous Thrombosis | Pulmonary Embolism

United States
GlaxoSmithKline

Completed

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery

Cardiovascular Disease
GlaxoSmithKline

Completed

Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients

Venous Thromboembolism

Japan
Paul Di Cesare,MD

Completed

The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

Total Knee Replacement

United States
GlaxoSmithKline
Sanofi

Completed

A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).

Thromboembolism
GlaxoSmithKline

Completed

Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

Ataxia
GlaxoSmithKline

Completed

Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

Ataxia
Melbourne Health

Terminated

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

Renal Failure

Australia
Duke University
GlaxoSmithKline

Completed

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction" (FONDA PK)

Renal Insufficiency

United States
Masonic Cancer Center, University of Minnesota

Completed

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Thromboembolism | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery (FONDACAST)

Thrombosis, Venous

Spain, Germany, Russian Federation, France, Italy, Netherlands
GlaxoSmithKline

Completed

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA/OASIS 8)

Acute Coronary Syndrome

Canada, France, Bulgaria, Germany, Poland, United Kingdom, Spain, Russian Federation, Korea, Republic of, Netherlands, India, United States, Brazil, Hungary, Italy, Argentina, Czech Republic, Greece
University of Alabama at Birmingham
GlaxoSmithKline

Terminated

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

Venous Thrombosis

United States
Schering-Plough

Withdrawn

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

Myocardial Infarction | Coronary Disease

United States, France, Canada
Mary Knudson, M.D.
GlaxoSmithKline

Completed

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

Venous Thromboembolism

United States
National Medical Research Center for Therapy and...

Completed

Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein

Endovenous Laser Ablation | Superficial Vein Thrombosis

Russian Federation
GlaxoSmithKline
Sanofi

Completed

OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

Thromboembolism
GlaxoSmithKline

Completed

Hemorrhage Risk Prescribed Arixtra

Thrombosis, Venous
University of Veterinary and Animal Sciences, Lahore...

Not yet recruiting

Evaluation of Licorice Root on Metabolic Syndrome in Polycystic Ovary Syndrome Females

Polycystic Ovary Syndrome | Metabolic Syndrome
GlaxoSmithKline

Completed

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Thrombosis, Venous

Japan
University of Delaware

Completed

Adverse Neurogenic Actions of Dietary Salt

Blood Pressure

United States
Children's Hospital of Philadelphia

Withdrawn

Gastrointestinal Implications of Voriconazole Exposure (GIVE)

Infection

United States
GlaxoSmithKline

Completed

Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism (FondaPPP)

Thromboembolism | Venous Thromboembolism

Germany
GlaxoSmithKline

Completed

The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Embolism, Pulmonary

Japan
GlaxoSmithKline

Completed

Fondaparinux EU-RMP (Adherence)

Acute Coronary Syndrome
Università degli Studi dell'Insubria

Terminated

Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency

Renal Insufficiency | Medical Patients

Italy
Duke University
GlaxoSmithKline

Withdrawn

Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

Kidney Diseases

United States
Indiana University School of Medicine
American Society for Bariatric Surgery

Withdrawn

Study to Determine Effective Dosing of Fondaparinux in Obese Persons

Morbid Obesity

United States
Centre Hospitalier Universitaire de Saint Etienne
GlaxoSmithKline

Completed

Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux. (PROPICE)

Major Orthopaedic Surgery and Renal Impairment

France
University of Louisville
James Graham Brown Cancer Center

Terminated

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Heparin-Induced Thrombocytopenia

United States
GlaxoSmithKline

Completed

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Thrombosis, Venous

Netherlands, Spain, Germany, Italy, Poland, Russian Federation, France, Israel, Estonia, Hungary, Slovakia, Latvia, Greece, Ukraine, Czech Republic, Switzerland, Bulgaria
The New England Baptist Hospital

Unknown

Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery (DVT)

Pulmonary Embolism

United States
Aga Khan University
Zeenat Qureshi Stroke Institute

Recruiting

Best Solution Identification to Prevent Hyperchloremia Combinations of Sodium Chloride and Sodium Acetate IV Fluids Along With Standard of Care Treatment in Acute Stroke Patients (sodium acetate)

Stroke, Acute

Pakistan
Shirley M. Tsunoda

Unknown

Drug Interaction With Envarsus XR and Grapefruit Juice

Kidney Transplant; Complications | Drug Interaction Food
National University of Malaysia

Completed

Safety of Fondaparinux as Post Partum Thromboprophylaxis

Thromboembolism in the Puerperium

Malaysia
Wayne State University
GlaxoSmithKline

Unknown

Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication

ICU Patients 18 Years or Older.

United States
Methodist Healthcare
University of Tennessee

Withdrawn

Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

Heparin-Induced Thrombocytopenia
Weill Medical College of Cornell University

Terminated

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) (IMPACT)

COVID-19

United States
Quovadis Associazione
Azienda Ospedaliera di Padova

Completed

Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 (VTE-COVID)

COVID-19 Disease | Thromboembolism, Venous

Italy
GlaxoSmithKline

Completed

Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Medstar Health Research Institute
GlaxoSmithKline

Completed

Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI (SWITCHIII)

Acute Coronary Syndromes

United States, Canada
Rigel Pharmaceuticals

Completed

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

T Cell Lymphoma

United States, Canada
GlaxoSmithKline

Completed

Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm

Fibrillation, Atrial

France, Germany
Queen Mary University of London

Not yet recruiting

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI)

Thrombosis | Injury Leg
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Sarcoma | Ovarian Cancer | Brain Tumor | Ototoxicity | Neuroblastoma | Liver Cancer | Central Nervous System Tumor | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

Canada, United States, Australia
Merck KGaA, Darmstadt, Germany

Completed

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Healthy

Germany
University of Delaware

Completed

Effects of Acute Dietary Sodium on Cerebrovascular Reactivity and Blood Pressure Reactivity

Blood Pressure | Cerebrovascular Reactivity

United States

3

Subscribe